Mrinal M. Gounder

TL;DR: Analysis of advanced cancer patients treated with immune-checkpoint inhibitors shows that tumor mutational burden, as assessed by targeted next-generation sequencing, predicts survival after immunotherapy across multiple cancer types.

TL;DR: A large-scale, prospective clinical sequencing initiative using a comprehensive assay, MSK-IMPACT, through which tumor and matched normal sequence data from a unique cohort of more than 10,000 patients with advanced cancer are compiled and identified clinically relevant somatic mutations, novel noncoding alterations, and mutational signatures that were shared by common and rare tumor types.

TL;DR: Safety, pharmacokinetics, RNAi mechanism of action, and clinical activity with a novel LNP-formulated RNAi therapeutic in patients with cancer are shown, providing proof-of-concept for RNAi therapeutics in humans and the basis for further development in cancer.

TL;DR: Treatment with theCDK4 inhibitor PD0332991 was associated with a favorable progression-free rate in patients with CDK4-amplified and RB-expressing WDLS/DDLS who had progressive disease despite systemic therapy.

TL;DR: A patient with an ETV6-NTRK3-driven mammary analogue secretory carcinoma to treatment with a pan-Trk inhibitor and the development of acquired resistance linked to a novel NTRK 3 mutation that interferes with drug binding is described.